Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13278879 | 1.00 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL13278753 | 1.00 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907960 | 0.92 | PTGDR2 (0.49) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907967 | 0.88 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907995 | 0.86 | PTGDR2 (0.52) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907972 | 0.85 | PTGDR2 (0.52) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907989 | 0.85 | PTGDR2 (0.52) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907926 | 0.82 | PTGDR2 (0.47) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907966 | 0.81 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907993 | 0.81 | PTGDR2 (0.50) | PTGDR2TBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697223-B1 | 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-A]INDOL ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-9096595-B2 | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD (CH) | 2015-08-04 | — | — | US | disclosed |
| EP-2697223-A1 | 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-A]INDOL ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2014-02-19 | — | — | EP | disclosed |
| US-20140045870-A1 | 7-(Heteroaryl-Amino)-6,7,8,9-Tetrahydropyrido[1,2-A]Indol Acetic Acid Derivatives and Their Use as Prostaglandin D2 Receptor Modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-13 | — | — | US | disclosed |
| WO-2012140612-A1 | 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-A]INDOL ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045870-A1 | 7-(Heteroaryl-Amino)-6,7,8,9-Tetrahydropyrido[1,2-A]Indol Acetic Acid Derivatives and Their Use as Prostaglandin D2 Receptor Modulators | PTGDR, PTGDR2, PTGER1 | PTGDR2 2/4885TBXA2R 6/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.